title: B cell depletion: rituximab in glomerular disease and transplantation.
abstract: B cells play a central role in the pathogenesis of many autoimmune diseases. Selective targeting can be achieved with the use of the monoclonal antibody rituximab. In addition to being a drug for non-Hodgkin's lymphoma, rituximab is also an FDA-approved treatment for refractory rheumatoid arthritis and, since recently, ANCA vasculitis. It has shown efficacy in many autoimmune diseases. This review will discuss current evidence and the rationale of the use of rituximab in glomerular diseases, including randomized controlled trials. The focus will be on the use of rituximab in idiopathic membranous nephropathy, systemic lupus erythematosus and ANCA-associated vasculitis. The emerging role of rituximab in renal transplantation, where it seems to be important for the desensitization protocols for highly sensitized patients as well as for the preconditioning of ABO-incompatible recipients and the treatment of antibody-mediated rejection, will also be addressed.
authors.affiliation: Department of Nephrology and Renal Transplant Unit, General Hospital 'Laiko', Athens, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Marinaki
authors.affiliation: Department of Nephrology and Renal Transplant Unit, General Hospital 'Laiko', Athens, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Skalioti
authors.affiliation: Department of Nephrology and Renal Transplant Unit, General Hospital 'Laiko', Athens, Greece.
authors.forename: J N
authors.initials: JN
authors.lastname: Boletis
keywords: ANCA-associated vasculitis; B cell depletion; Lupus nephritis; Membranous nephropathy; Rituximab; Transplantation